Fund focus: LPs flock to Lake Bleu’s late show
Lake Bleu Capital leveraged a lift in Chinese healthcare sentiment to raise $560 million for a fund that will target late-stage healthcare investments
More than 40 Chinese biotech and medtech companies have gone public in the last two years. Only five opted for NASDAQ. The rest headed for Hong Kong, most taking advantage of a regulatory provision that...
More on Greater China
Latest News
China AI drug discovery platform StoneWise raises $100m
StoneWise, a Chinese biotech start-up that uses artificial intelligence (AI) technology to develop new drugs, has raised $100 million in Series B funding across two tranches.
Media SPAC legitimizes MENA for Asia investors
The imminent US listing of a Middle East and North Africa (MENA) media app via a special purpose acquisition company (SPAC) is helping legitimize the region for Asian private equity.
Australia's Quadrant loses growth fund head
Justin Ryan, a managing partner at Quadrant Private Equity and latterly head of the Australian firm’s growth strategy, is stepping back from day-to-day investment activity.
KKR joins $61m round for Japan's Netstars
KKR has contributed JPY4 billion ($37 million) to a JPY6.6 billion funding round for Netstars, a Japanese QR code payment gateway operator. SIG and Lun Partners, a Hong Kong-based global financial technology investor, also took part.